GSK and Dynavax Technologies reported that their drug candidate Z-1018 shows promise against Shingrix.
2 reports, 2 independent
Updated Aug 22
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
GSK and Dynavax Technologies reported that their drug candidate Z-1018 shows promise against Shingrix.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Z-1018, a drug candidate involving GSK and Dynavax, shows promise against Shingrix.1 source
Z-1018 demonstrated comparable immunogenicity and favorable tolerability against Shingrix.1 source
Keep exploring
The entities involved
-
GSK
British multinational pharmaceutical and biotechnology company
-
Dynavax Technologies (United States)
company in Berkeley, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- Clinical Trials ArenaDynavax’s shingles vaccine shows promise in trial against GSK’s Shingrix Dynavax Technologies has revealed promising topline outcomes from the initial part of its Phase I/II clinical trial, comparing
- PR NewswireDynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile At all doses and formulations evaluated in Part 1 of the trial, Z-1018 was well-tolera